14 July 2021
EMA/CAT/396514/2021
Human Medicines Division

Committee for Advanced Therapies (CAT)

Draft agenda for the meeting on 14-16 July 2021

Chair: Martina Schüßler-Lenz; Vice-Chair: Ilona Reischl

14 July 2021, 14:00 – 18:00, remote virtual meeting

15 July 2021, 09:00 – 18:00, remote virtual meeting

16 July 2021, 09:00 – 13:00, remote virtual meeting

Disclaimers

Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CAT meeting reports once the procedures are finalised.

Of note, this agenda is a working document primarily designed for CAT members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

Table of contents

1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the CAT plenary session to be held 14-16 July 2021. See July 2021 CAT minutes (to be published post September 2021 CAT meeting).

1.2. Adoption of agenda

CAT agenda for 14-16 July 2021 meeting

1.3. Adoption of the minutes

CAT minutes for 16-18 June 2021 meeting

2. Evaluation of ATMPs

2.1. Opinions

No items

2.2. Oral explanations

No items

2.3. Day 180 list of outstanding issues

2.3.1. Autologous glioma tumor cells, inactivated / autologous glioma tumor cell lysates, inactivated / allogeneic glioma tumor cells, inactivated / allogeneic glioma tumor cell lysates, inactivated - Orphan - EMEA/H/C/003693

Epitopoietic Research Corporation-Belgium (E.R.C.); treatment of glioma

Scope: Day 180 list of outstanding issues

Action: for adoption

List of Questions adopted on 22.01.2021.

2.4. Day 120 list of questions

No items

2.5. Day 80 assessment reports

No items

2.6. Update on ongoing initial applications

2.6.1. Eladocagene exuparvovec - Orphan - EMEA/H/C/005352

PTC Therapeutics International Limited; treatment of aromatic L-amino aciddecarboxylase (AADC) deficiency

Scope: Request for a (2-month) clock stop extension

Action: for adoption

List of outstanding issues adopted on 16 April 2021

2.7. New applications

2.7.1. Valoctocogene roxaparvovec – Orphan - EMEA/H/C/005830

Accelerated assessment

BioMarin International Limited; intended for treatment of severe haemophilia A

Scope: Timetable for assessment

Action: for adoption

2.8. Withdrawal of initial marketing authorisation application

No items

2.9. Re-examination of initial application procedures under Article 9(2) of Regulation No. 726/2004

No items

2.10. GMP and GCP inspections requests

No items

2.11. Type II variations and variations of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

2.11.1. Imlygic - talimogene laherparepvec - EMEA/H/C/002771/II/0044

Amgen Europe B.V.

Rapporteur: Heli Suila, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: PhV. Opinion

Submission of the final report from study 20180099 listed as a category 3 study in the RMP. This is a cross-sectional survey to evaluate physician knowledge of safety messages included in the physician education booklet (PEB) for Imlygic.

Action: for adoption

Request for supplementary information adopted on 12.05.2021.

2.11.2. Zolgensma - onasemnogene abeparvovec - Orphan - EMEA/H/C/004750/II/0015

Novartis Gene Therapies EU Limited

Rapporteur: Carla Herberts

Scope: Clinical. Request for supplementary information (RSI)

Updates to Sections 4.4, 4.8 and 5.1 of the SmPC to reflect the final study results Study AVXS-101-CL-302: a post-authorisation efficacy study intended to confirm the efficacy and safety and tolerability of a single dose of Zolgensma in patients younger than 6 months of age with SMA Type 1 with One or Two SMN2 Copies.
The package leaflet has been updated accordingly and annex II has been updated to reflect completion of this Specific Obligation.

Action: for adoption

2.11.3. Tecartus (autologous anti-CD19-transduced CD3+ cells); Yescarta (axicabtagene ciloleucel)- EMEA/H/C/WS2071

Kite Pharma EU B.V.

CAT Rapporteur: Jan Mueller-Berghaus

Scope: Quality. Request for supplementary information (RSI)

Action: for adoption

2.12. Extension applications

No items

2.13. Other Post-Authorisation Activities

2.13.1. Alofisel - darvadstrocel - Orphan - EMEA/H/C/004258/REC/006

Takeda Pharma A/S

Rapporteur: Lisbeth Barkholt, CHMP Coordinator: Kristina Dunder

Scope: Quality

Action: for adoption

2.13.2. Kymriah - tisagenlecleucel - Orphan - EMEA/H/C/004090/MEA/005.1

Novartis Europharm Limited

Rapporteur: Rune Kjeken, CHMP Coordinator: Ingrid Wang

Scope: Safety

MAH Response to MEA-005 [Interim report, Study CCTL019A2205B] as adopted in February 2021.

Action: for adoption

2.13.3. Tecartus - autologous peripheral blood T cells CD4 and CD8 selected and CD3 and CD28 activated transduced with retroviral vector expressing anti-CD19 CD28/CD3-zeta chimeric antigen receptor and cultured - Orphan - EMEA/H/C/005102/MEA/005

Kite Pharma EU B.V.

Rapporteur: Jan Mueller-Berghaus, CHMP Coordinator: Jan Mueller-Berghaus

Scope: Safety

From Initial MAA:
Prescriber Survey: Assess the prescribers' understanding of the risks of KTE-X19. Evaluate the effectiveness of risk minimization activities: HCP educational materials, and Patient Alert Card.
Protocol/ study number KT-EU-472-5966

Action: for adoption

2.13.4. Zynteglo - betibeglogene autotemcel - Orphan - EMEA/H/C/003691/REC/014

bluebird bio (Netherlands) B.V

Rapporteur: Carla Herberts, CHMP Coordinator: Paula Boudewina van Hennik

Scope: Quality

Action: for adoption

2.13.5. Zynteglo - betibeglogene autotemcel - Orphan - EMEA/H/C/003691/R/0018

bluebird bio (Netherlands) B.V

Rapporteur: Carla Herberts, Co-Rapporteur: Violaine Closson-Carella, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: 1-year Renewal of Marketing Authorisation. Opinion

Action: for adoption

Request for Supplementary Information adopted on 22.01.2021.

Note: an article 20 referral procedure was initiated by the Commission, asking EMA to confirm the benefit risk profile of Zynteglo in the light of the new safety finding. The renewal procedure was put on hold until the referral procedure was finalised. See 2.13.6.

2.13.6. Zynteglo - betibeglogene autotemcel - Orphan – EMEA/H/C/003691/A20/0023

bluebird bio (Netherlands) B.V

CAT-PRAC group: CAT: Carla Herberts (Rapporteurs) and Violaine Closson-Carella (Co-Rapporteur), Alessandro Aiuti; PRAC: Brigitte Keller-Stanislawski, Menno van der Elst

Scope: referral procedure under Article 20 PhV

Action: for adoption

2.13.7. Evaluation and grading of neurotoxicities for CAR-T cells ATMPs – a proposal for using ICANS

Scope: ICANS in CAR-T post-autorisation reports

3. Action: for discussionCertification of ATMPs

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

3.1. Opinion

No items

3.2. Day 60 Evaluation Reports

No items

3.3. New Applications

No items

4. Scientific Recommendation on Classification of ATMPs

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

4.1. Next deadline for submission of new requests is 29 July 2021. These will appear in the CAT Written Procedure of August 2021.New requests – Appointment of CAT Coordinator

No items

4.2. Day 30 ATMP scientific recommendation

4.2.1. Autologous population of selected renal cells (SRC)

Intended for the treatment of chronic kidney disease (CKD)

Scope: ATMP scientific recommendation

Action: for adoption

4.2.2. Autologous adipose mesenchymal stem cells (MSCs)

Indicated for cartilage defects of degenerative origin and for the treatment of osteoarthritis

Scope: ATMP scientific recommendation

Action: for adoption

4.2.3. Allogeneic natural killer cells armed with anti-CD20 monoclonal antibody

Intended for the treatment of B-Cell Non-Hodgkin lymphoma

Scope: ATMP scientific recommendation

Action: for adoption

4.2.4. Recombinant serotype 9 adeno-associated virus encoding a codon-optimised human galactosylceramidase transgene [ssAAV9/CBA-hsaGALCopt2-SV40p (AAV9-hGALC)]

Intended for the treatment of Krabbe disease

Scope: ATMP scientific recommendation

Action: for adoption

4.2.5. Minimally manipulated autologous pancreatic islets

Intended for the treatment of chronic pancreatitis and recurrent acute pancreatitis immediately following pancreatectomy

Scope: ATMP scientific recommendation

Action: for adoption

4.2.6. Extracellular matrix and non-viable osteogenic cells derived from human adipose-derived stem cells, associated with hydroxyapatite/beta-tricalcium phosphate (HA/βTCP) particles

Intended to stimulate bone regeneration in pathological hypoxic and/or necrotic bone conditions

Scope: ATMP scientific recommendation

Action: for adoption

4.2.7. HEK293 cells transfected with a lentiviral vector to express the tumour-specific antigen, WT1 and the antigen presenting molecule, cluster of differentiation 1d (CD1d).

Intended for the treatment of WT1-expressing tumours

Scope: ATMP scientific recommendation

Action: for adoption

4.2.8. Ribonucleoprotein (RNP), a complex of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Cas 9 and sgRNA, delivered by a novel synthetic non-viral vector, for the excision of exon 80 of the human COL7A1 gene

Intended for the treatment of recessive dystrophic epidermolysis bullosa (RDEB)

Scope: ATMP scientific recommendation

Action: for adoption

4.2.9. Isolated CD31+ cells

Intended for the treatment of erectile dysfunction

Scope: ATMP scientific recommendation – list of questions

Action: for adoption

4.2.10. Live human mesenchymal stem cells derived from allogeneic Wharton's jelly

Intended for the treatment of rheumatoid arthritis, unspecified

Scope: ATMP scientific recommendation

Action: for adoption

4.2.11. Live human mesenchymal stem cells derived from allogeneic Wharton's jelly

Intended for the treatment of systemic lupus erythematosus, unspecified

Scope: ATMP scientific recommendation

Action: for adoption

4.2.12. Live human mesenchymal stem cells derived from allogeneic Wharton's jelly

Intended for the treatment of systemic sclerosis, unspecified

Scope: ATMP scientific recommendation

Action: for adoption

4.3. Day 60 revised scientific recommendation (following list of questions)

No items

4.4. Finalisation of procedure

4.4.1. Nanoparticle consisting of non-pseudotyped (bald) lentiviral vector encoding for a CD19 CAR , encapsulated

Intended for the treatment of CD19+ B-cell malignancy

Scope: The European Commission raised no comments. ATMP scientific recommendation

Action: for information

4.4.2. Autologous T cells genetically modified ex vivo using a synthetic chromosome encoding CCR6, IL-2, a truncated version of CD34 and two independent inducible safety switches

Intended for treatment of patients with solid tumours for which a draining lymph node can be identified. Initially the product will be developed for colon cancer and urinary bladder cancer

Scope: The European Commission raised no comments. ATMP scientific recommendation.

Action: for information

4.4.3. Live human mesenchymal stem cells derived from allogeneic Wharton's jelly

Intended for treatment of atherosclerosis of the arteries of the lower extremities

Scope: The European Commission raised no comments. ATMP scientific recommendation.

Action: for information

4.5. Follow-up and guidance

4.5.1. Allogeneic corneal endothelial cells in a confluent monolayer adhering to a cornea-shaped sheet of cross-linked collagen

Intended for the treatment of corneal dysfunction

Scope: Request for clarification from the applicant

Action: for discussion

Note: Following the transmission of the final classification report, the company contacted EMA asking for clarification

5. Scientific Advice

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

5.1. New requests - appointment of CAT Rapporteurs

5.1.1. Ongoing scientific advice procedures - Appointment of CAT Peer Reviewers

Timetable:

-Start of procedure at SAWP:	05-08.07.2021
-Appointment of CAT Peer-Reviewers:	16.07.2021
-SAWP first reports:	23.08.2021
-CAT Peer-Reviewer's comments:	27.08.2021
-Discussion at SAWP:	30 Aug.-02 Sept.2021
-Discussions at CAT and feedback from SAWP:	10.09.2021

5.1.2. Scientific advice procedures starting at the next SAWP meeting

Timetable:

- Start of procedure at SAWP:	30.08-02.09.2021
- Appointment of CAT Peer Reviewers:	08-10.09.2021
- SAWP first reports:	20.09.2021
- CAT Peer Reviewer comments:	24.09.2021
- Discussion at SAWP:	27-30.09.2021
- Discussion at CAT and feedback to SAWP:	08.10.2021

Additional procedures starting at the next SAWP meeting will be included in the agenda of the August written procedure.

5.2. Procedures discussed at SAWP – 1st report and D40 JRs, LoOIs

5.3. Finalisation of D70 procedures – feedback from the discussion meeting

5.4. Final Advice Letters for procedures finalised the previous month

6. Pre-Authorisation Activities

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

6.1. Paediatric investigation plans

No items

6.2. ITF briefing meetings in the field of ATMPs

6.3. Priority Medicines (PRIME) – Eligibility requests

6.3.1. Month 0 - Start of the procedure

Timetable for assessment:

Procedure start:	08.07.2021
SAWP recommendation:	02.09.2021
CAT recommendation:	10.09.2021
CHMP adoption of report and final recommendation:	16.09.2021

6.3.2. Month 1 – Discussion of eligibility

6.3.3. Month 2 – Recommendation of eligibility

No items

6.3.4. Ongoing support

7. Organisational, regulatory and methodological matters

7.1. Mandate and organisation of the CAT

7.1.1. Joint CAT-CHMP Strategic Review & Learning (virtual) meeting (SRLM) under the Slovenian presidency, 20-21 October 2021, Ljubljana (Slovenia)

CAT: Metoda Lipnik-Štangelj, Martina Schuessler-Lenz

Scope: Practical information and agenda content

Action: for discussion

7.1.2. CAT's August 2021 written procedure

Scope: August 2021: process and timelines

Action: for adoption

7.2. Coordination with EMA Scientific Committees

7.2.1. CHMP learnings that impact CAT decisions

CAT: Jan Mueller-Berghaus, Romaldas Mačiulaitis, John-Joseph Borg, Bruno Sepodes, Sol Ruíz

Scope: CHMP learnings with relevance to CAT

Action: for information

7.2.2. Scientific Coordination Board (SciCoBo) – meeting of 29th June 2021

CAT: Martina Schuessler-Lenz

Scope: feedback on the discussions in the SciCoBo meeting

Action: for discussion

7.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

7.3.1. Working Party with Patients' and Consumers' Organisations (PCWP) and Working Party with Healthcare Professionals' Organisations (HCPWP)

Scope: minutes of the PCWP/HCPWP joint meeting that took place on 01-02 June 2021

Action: for information

7.3.2. Reflection paper on criteria to be considered for the evaluation of new active substance (NAS) status of biological substances

BWP: Roeland Martijn Van der Plas

Scope: Reflection paper on evaluation of NAS status of biological substances (including ATMPs)

Action: For discussion/adoption

7.4. Cooperation with the EU regulatory network

7.4.1. EC Complex clinical trials (CCT) questions and answers document – involvement in subgroup of clinical trial expert group (CTEG)

Scope: Introduction and call for interest

Action: for discussion

7.4.2. Update on Commission's work on interplay GMO-pharma

Action: for information

7.5. Cooperation with international regulators

7.5.1. ATMP cluster teleconference with US-FDA, Health Canada and PMDA (Japan)

CAT: Martina Schuessler-Lenz

Scope: draft agenda of the teleconference that will take place on 22 July 2021

Action: for discussion and nomination of CAT participants

7.5.2. International Pharmaceutical Regulators Programme (IPRP) – Gene therapy and cell therapy working group

CAT: Pille Säälik, Ivana Haunerova

Scope: Agenda of the international teleconference that will take place on 22 July 2021

Action: for discussion

7.6. CAT work plan

7.6.1. Real World Data (RWD) in regulatory decision making of ATMPs

CAT: Martina Schuessler-Lenz

Scope: Feedback from the kick-off meeting

Action: for information

7.7. Planning and reporting

7.7.1. DIA Global Annual meeting 2021 – Session on Gene Therapy, 18 June 2021

CAT: Martina Schuessler-Lenz

Scope: 'Gene Therapy: Getting Back on Track After COVID-19'. Learning objective: discuss the effect of the COVID-19 pandemic on the development of gene therapies; Identify the need for new policy initiatives to help expedite the gene therapies both in the US and globally. Moderator: Janet Lynch Lambert (Alliance for Regenerative Medicine; ARM). Panellists: Peter W. Marks (Center for Biologics Evaluation and Research; CBER-FDA), Adora Ndu (Biomarin) and Martina Schuessler-Lenz

Action: for information

Note: the session was pre-recorded on 8th June 2021.
Link: Gene Therapy: Getting Back on Track After COVID-19 (diaglobal.org)

7.7.2. CASSS: Cell and Gene Therapy Products: Manufacturing, Quality and Regulatory Considerations, 8-10 June 2021

CAT: Heli Suila

Scope: feedback from the meeting

Action: for information

7.7.3. European Health Forum Gastein (EHFG) – Health Talks: 'Transforming the future of healthcare – do cell and gene therapies hold the key?', 15 June 2021

CAT: Ilona Reischl

Scope: feedback from the meeting

Action: for information

7.7.4. 6th Industry Stakeholder Platform on the operation of the centralised procedure for human medicines – 'Experience and perceptions from the industry on the use of Accelerated Assessment and Conditional Marketing Authorisation, 30 June 2021

CAT: Martina Schuessler-Lenz

Scope: feedback from the meeting

Action: for information

7.8. Others

7.8.1. CAT stakeholder meeting October 2021

CAT: Martina Schuessler-Lenz

Scope: identification of topics

Action: for discussion

Note: One of the topics is linked to the CAT work plan: Real World Data (RWD) in regulatory decision making of ATMPs.

8. Any other business

No items

Date of next CAT meeting:

08-10/09/2021

9. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

Abbreviations / Acronyms

AAV: Adeno-Associated Virus

AR: Assessment Report

ATMP: Advanced Therapy Medicinal Product

BWP: Biologics Working Party

CAT: Committee for Advanced Therapies

CHMP: Committee for Medicinal Product for Human Use

COMP: Committee for Orphan Medicinal Products

CTFG: Clinical Trial Facilitation Group

DG: Drafting Group

EC: European Commission

EU NTC: European Union Network Training Centre

ERA: Environmental Risk Assessment

FDA: Food and Drug Administration

FL: Final Letter

GCG: Guideline Consistency Group

GCP: Good Clinical Practice

GLP: Good Laboratory Practice

GMO: Genetically-modified organism

GMP: Good Manufacturing Practice

GTMP: Gene Therapy Medicinal Product

HTA: Health Technology Assessment Bodies

HSPC: Hematopoietic Stem and Progenitor Cells

ITF: Innovative Task Force

JR: Joint Report

LoOI: List of outstanding issues

LoQ: List of questions

MA: Marketing Authorisation

MAA: Marketing Authorisation Application

MAH: Marketing Authorisation Holder

MNAT: Multinational assessment team

MSC: Mesenchymal stem cells

PDCO: Paediatric Committee

PMDA: Pharmaceuticals and Medical Devices Agency (Japan)

PIP: Paediatric Investigation Plan

PL: Package leaflet

PRAC: Pharmacovigilance and Risk Assessment Committee #

PRIME: Priority Medicines

QRD: Quality review of documents

RMP: Risk Management Plan

RP: Reflection paper

RSI: Request for supplementary information

SAs: Scientific Advices

SAG-O: Scientific Advisory Group Oncology

SAWP: Scientific Advice Working Party

SR: Summary Report

SWP: Safety Working Party

SME: Small and medium size enterprises

SmPC: Summary of Products Characteristics

TT: Timetable

Evaluation of ATMPs (section 2)

This section lists applications for marketing authorisations of new Advanced Therapy Medicinal Products (ATMPs) that are to be discussed by the Committee. It also lists any ATMP related inspection requests (section 2.9) and Post-authorisation activities (section 2.10).

New applications (sections 2.1. to 2.12.)

Section 2.1 is for ATMPs nearing the end of the evaluation and for which the CAT is expected to adopt a draft **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CAT opinion is transmitted to the CHMP for final adoption. The CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU. More information on the evaluation of ATMPs can be found here.

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CAT. The clock stop happens after day 120 and may also happen after day 180, when the CAT has adopted respectively a **Day 120 list of questions** (section 2.3) or a List of outstanding issues to be addressed by the company, which is listed in the agenda under sections 2.7 (**Ongoing evaluation procedures**). Section 2.7 also includes the CAT discussions at any other timepoint of the evaluation procedure of new applications.

Oral explanation (section 2.2.)

Prior to adoption of the CAT opinion, marketing authorisation applicants are normally invited to the CAT plenary meeting to address questions raised by the Committee.

Oral explanations normally relate to ongoing applications, but they can also relate to any other issue for which the CAT would like to discuss with company representatives in person.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 (section 2.6.)

This section lists applications for new marketing authorisation for ATMPs for which the applicant has requested a re-examination of the opinion previously issued by the CHMP. Similar to the initial evaluation of a marketing authorisation of an ATMP, CAT will adopt a draft re-examination opinion, which is transmitted to the CHMP for final adoption.

Withdrawal of applications (section 2.7.)

This section includes information on marketing authorisation applications that are withdrawn by the applicant. Applicants may decide to withdraw applications at any stage during the assessment and a CAT opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

New applications (section 2.9.)

In this section, information is included on upcoming marketing authorisation applications for ATMPs, as well as information on appointment of Rapporteurs for new ATMP applications.

GMP and GCP Inspections Issues (section 2.10.)

This section lists inspections that are undertaken for ATMPs. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Post-authorisation activities (section 2.12.)

This section lists type II variations, extension application according to Annex I of Reg. 1234/2008, re-examination procedures for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP and other issues concerning authorised medicines that are not covered elsewhere in the agenda such as annual reassessments, 5-year renewals, supply shortages, qualify defects. Issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines, will also be included here.

Certification of ATMPs (section 3)

This section includes the scientific evaluation by the CAT of quality and non-clinical data that small and medium-sized enterprises have generated at any stage of the ATMP development process. More information on the ATMP certification procedure can be found here.

Scientific Recommendation on Classification of ATMPs (Section 4)

This section includes the scientific recommendation by the CAT on whether medicines based on genes, cells or tissues meet the scientific criteria that define ATMPs. More information on the ATMP classification procedure, including the outcomes of finalised classifications, can be found here.

Scientific Advice (section 5)

This section includes all scientific advice given to companies during the development of an ATMP. Information related to the number of ATMP related scientific advices discussed by CAT can be found in the CAT Monthly reports. Further information on SAWP can be found here.

Pre-Authorisation (section 6)

Paediatric Investigation Plan (PIP)

This section includes the discussion of an ATMP before a formal application for marketing authorisation

is submitted. These cases refer for example to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation: in case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

CAT contributes to the evaluation of a Paediatric Investigation Plan (PIPs) for ATMPs by the Paediatric Committee. These PIPs are included in this section of the Agenda.

ITF Briefing meeting in the field of ATMPs

This section refers to briefing meetings of the Innovation Task Force and International co-operations activities of the CAT

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes of meetings with applicants developing ATMPs and of other ITF meetings of interest to the CAT are included in this section of the agenda. Further information on the ITF can be found here.

Priority Medicines (PRIME)

This section includes the new requests for eligibility to PRIME for ATMPs under development, the discussions in CAT of these eligibility requests and the final recommendations for eligibility of ATMPs adopted by CHMP.

CAT will appoint one of its members as the CAT sponsor for each new ATMP eligibility request who will lead the CAT discussion based on the recommendation from the SAWP.

Organisational, regulatory and methodological matters (section 7)

This section includes topics related to regulatory and procedural guidance, CAT workplan, CAT meeting organisation (including CAT membership), planning and reporting, co-ordination with other committees, working parties and scientific advisory groups.

Furthermore, this section refers to the activities of the CAT drafting groups developing scientific guidelines for gene therapy medicinal products and for cell-based medicinal products, cooperation within the EU regulatory network and international regulators as well as direct interaction with interested parties. It also includes topics of scientific interest for the Committee that are not directly related to the work of the CAT drafting groups or CAT associated working parties.

Any other business (section 8)

This section is populated with miscellaneous topics not suitable under the previous headings.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/